P109 - Comparing Characteristics and Prescribing Patterns Among Patients with T2D and Established ASCVD with and without Cardioprotective Medications

Using real-world data, we aimed to elucidate differences in demographic/clinical characteristics and prescription patterns between patients with T2D and ASCVD in the US receiving SGLT2is and/or GLP-1 RAs and patients not receiving SGLT2is and/or GLP-1 RAs. We found that patients with a history of myocardial infarction and peripheral artery disease were more likely to use cardioprotective diabetes treatments. Patients receiving SGLT2is and/or GLP-1 RAs had lower baseline CCI scores, but a higher frequency of several diabetes-related conditions. Patients who received SGLT2is and/or GLP-1 RAs following an ASCVD diagnosis were more likely to be prescribed other antidiabetic medications. Patients receiving SGLT2is and/or GLP-1 RAs may be further along in their T2D care pathway as indicated by their longer treatment duration.